文献速递腹部MR

钆塞酸增强MRI的T2 mapping预测肝硬化失代偿与死亡

T2 mapping in gadoxetic acid-enhanced MRI: utility for predicting decompensation and death in cirrhosis.
PubMed 文献 · Eur Radiol · 2021-03-29

回顾性纳入292例肝硬化患者,在钆塞酸增强MRI肝期10分钟行T1及T2 mapping并测量肝、脾T1/T2值,分析其与失代偿和死亡的关系。延长T2Liver是失代偿(HR 2.59)和死亡(HR 2.61)的独立预测因子,联合白蛋白及MELD评分构建风险模型(失代偿阈值49.3 ms、死亡阈值57.4 ms)。

要点

  • 肝期10分钟T2 mapping测得的T2Liver升高与肝硬化失代偿和死亡独立相关。
  • 失代偿风险模型以T2Liver 49.3 ms为界,死亡风险模型以57.4 ms为界分组。
  • 高、低风险组至失代偿和死亡的平均时间差异有统计学意义(p < 0.001)。

关键影像表现/征象

  • 径向TSE T2 mapping序列(分层回波共享与伪黄金角重排)测得的肝脏T2值在失代偿期肝硬化中显著高于代偿期肝硬化。
  • 基线代偿期肝硬化患者中9.6%(19/197)在平均18.7个月随访期内发生失代偿。
  • 全部患者中5.1%(15/292)在平均19.2个月随访期内死亡。

诊断标准与关键数值

  • 延长T2Liver预测失代偿的HR为2.59(95%CI 1.26–5.31),白蛋白HR 0.28(95%CI 0.12–0.68)、MELD评分HR 1.34(95%CI 1.08–1.66)亦为独立预测因子。
  • T2Liver预测死亡的HR为2.61(95%CI 1.19–5.72),白蛋白HR 0.46(95%CI 0.19–1.14)为独立预测因子。
  • 失代偿风险模型以T2Liver 49.3 ms为界分为< 49.3与≥ 49.3 ms两组。
  • 死亡风险模型以T2Liver 57.4 ms为界分为< 57.4与≥ 57.4 ms两组。
  • 高、低风险组平均至失代偿时间12.9 vs 29.2个月、平均至死亡时间16.5 vs 29.6个月,差异有统计学意义(p < 0.001)。

临床应用与阅片要点

  • 肝硬化患者肝脏MRI可加做肝期10分钟T2 mapping,测量T2Liver作为无创预后标志物。
  • T2Liver结合血清白蛋白与MELD评分可用于失代偿和死亡的风险分层。
  • 原文推荐将T2 mapping作为肝硬化患者肝脏MRI检查的一部分。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether T2 mapping in liver MRI can predict decompensation and death in cirrhotic patients.

METHODS: This retrospective study included 292 cirrhotic patients who underwent gadoxetic acid-enhanced MRI, including T1 and T2 mapping at 10-min hepatobiliary phase by using the Look-Locker and radial turbo spin-echo sequences, respectively. T1 and T2 values of the liver and spleen were measured. The association of MR parameters and serum markers with decompensation and death was investigated. Risk models combining T2Liver, serum albumin level, and Model for End-Stage Liver Disease (MELD) score were created for predicting decompensation (T2Liver, < 49.3 versus ≥ 49.3 ms) and death (< 57.4 versus ≥ 57.4 ms).

RESULTS: In patients with compensated cirrhosis at baseline and in the full patient cohort, 9.6% (19 of 197) and 5.1% (15 of 292) developed decompensation and died during the mean follow-up periods of 18.7 and 19.2 months, respectively. A prolonged T2Liver (hazard ratio (HR), 2.59; 95% confidence interval (CI), 1.26, 5.31) was independently predictive of decompensation along with the serum albumin level (HR, 0.28; 95% CI, 0.12, 0.68) and MELD score (HR, 1.34; 95% CI, 1.08, 1.66). T2Liver (HR, 2.61; 95% CI, 1.19, 5.72) and serum albumin level (HR, 0.46; 95% CI, 0.19, 1.14) were independent predictors of death. The mean times to decompensation (12.9 versus 29.2 months) and death (16.5 versus 29.6 months) were significantly different between the high- and low-risk groups (p < 0.001).

CONCLUSION: T2Liver from T2 mapping can predict decompensation and death in patients with cirrhosis.

KEY POINTS: • Liver T2 values from the radial turbo spin-echo (TSE) T2 mapping sequence with tiered echo sharing and pseudo golden-angle (pGA) reordering were significantly higher in decompensated cirrhosis than compensated cirrhosis. • Liver T2 values from the radial TSE T2 mapping sequence with tiered echo sharing and pGA reordering can predict decompensation and death in patients with cirrhosis. • T2 mapping is recommended as part of liver MRI examinations for cirrhotic patients because it can provide a noninvasive prognostic marker for the development of decompensation and death.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yang W, Kim JE, Choi HC, et al. T2 mapping in gadoxetic acid-enhanced MRI: utility for predicting decompensation and death in cirrhosis. Eur Radiol. 2021. PMID: 33782768. doi:10.1007/s00330-021-07805-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。